Data from collaboration with ADC Therapeutics presented at the EORTC-NCI-AACR Symposium showed SonoTran® increased potency of ADCT-601 by 3.3 timesOXFORD, UK , October 31, 2022 / B3C newswire / OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasou.